Cartesian Therapeutics Inc.
$ 7.55
8.17%
24 Feb - close price
- Market Cap 196,327,000 USD
- Current Price $ 7.55
- High / Low $ 7.75 / 6.91
- Stock P/E N/A
- Book Value -1.38
- EPS -1.33
- Next Earning Report 2026-03-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -70.29 %
- 52 Week High 18.97
- 52 Week Low 5.98
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$35.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-14 | 2025-05-08 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-07 | 2023-11-13 | 2023-08-17 | 2023-05-04 | 2023-03-02 |
| Reported EPS | -1.38 | -0.7724 | -0.65 | -0.5935 | -0.42 | 0.64 | -0.8 | -0.07 | -0.06 | -0.07 | -0.14 | 0.04 |
| Estimated EPS | -0.9 | -0.82 | -0.71 | -0.8257 | -0.55 | -0.09 | -1.42 | -0.04 | -0.06 | -0.08 | -0.09 | -0.07 |
| Surprise | -0.48 | 0.0476 | 0.06 | 0.2322 | 0.13 | 0.73 | 0.62 | -0.03 | 0 | 0.01 | -0.05 | 0.11 |
| Surprise Percentage | -53.3333% | 5.8049% | 8.4507% | 28.1216% | 23.6364% | 811.1111% | 43.662% | -75% | 0% | 12.5% | -55.5556% | 157.1429% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNAC
2026-02-23 15:19:43
Cartesian Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences in March and April 2026. Management will present at the 46th Annual TD Cowen Health Care Conference and participate in fireside chats at Leerink’s Global Healthcare Conference and the 25th Annual Needham Virtual Healthcare Conference. Live webcasts and archived replays of these events will be available on the company's website.
2026-02-23 11:38:13
Cartesian Therapeutics, a clinical-stage biotechnology company, announced its management will participate in three investor conferences in March and April 2026. These include the 46th Annual TD Cowen Health Care Conference, Leerink’s Global Healthcare Conference, and the 25th Annual Needham Virtual Healthcare Conference, where they will give presentations and fireside chats. Webcasts and replays of these events will be available on the company's website.
2026-02-12 04:28:17
FMR LLC (Fidelity) has strategically reduced its stake in Cartesian Therapeutics Inc (RNAC) by selling 788,794 shares at $7.21 each on December 31, 2025. This adjustment leaves FMR LLC with 1,366,989 shares, now 5.30% of its portfolio, reflecting a reassessment of RNAC's prospects due to its "significantly overvalued" status and poor financial health. Cartesian Therapeutics, a clinical-stage biopharmaceutical company, faces significant financial distress with a low GF Score and negative Altman Z score.
2026-02-05 19:27:07
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) has received an average rating of "Moderate Buy" from analysts, with four buy recommendations and one sell recommendation, and an average one-year price target of $38.50. Recent analyst revisions include BTIG raising its target to $44, Needham to $42, and HC Wainwright reducing its target to $30. Insider activity shows CFO Blaine Davis recently sold 10,591 shares, reducing his position by 8.03%, while institutional investors hold 86.95% of the stock.
2026-02-03 19:59:42
Cartesian Therapeutics, Inc. announced the granting of inducement awards to two new employees. These awards include options to purchase an aggregate of 12,050 shares of the Company's common stock at an exercise price of $6.79. The options will vest over four years, with the first 25% vesting on February 2, 2027, and the remainder vesting in monthly installments.
2026-02-03 07:50:16
Cartesian Therapeutics (NASDAQ:RNAC) shares dropped 0.6% in mid-day trading on Monday, with trading volume significantly below its daily average. The company recently reported an EPS miss but beat revenue estimates, and its CFO sold a portion of his shares. Analysts have a mixed outlook but the consensus remains a "Moderate Buy" with an average target price of $38.50.
